AOD-9604 is a 15-amino-acid fragment corresponding to residues 177 to 191 of human growth hormone, modified at the C-terminus, and it was studied through preclinical lipolysis work in obese mice before moving into a human metabolic Phase 2 program. The mouse data measured fat oxidation, body weight and lipid mobilization directly; the human Phase 2 program measured body composition change over a multi-month study window in people with excess body fat. The two bodies of evidence answer different questions, and the preclinical mouse work remains the more completely documented half of the record in the peer-reviewed literature.
| Key fact | What the record shows | Source |
|---|---|---|
| Structure | Synthetic fragment of human growth hormone, residues 177-191, with a modified C-terminus to block growth-promoting activity | Heffernan et al., 2001 (PubMed 11713213) |
| Mechanism studied | Lipolytic activity in adipose tissue without activating the full-length growth hormone receptor's growth-promoting signaling | Heffernan et al., 2001 (PubMed 11713213) |
| Animal model used | Diet-induced obese mice and beta-3 adrenergic receptor knockout mice, chronic treatment design | Heffernan et al., 2001 (PubMed 11713213; PubMed 11673763) |
| Reported preclinical finding | Reduced fat mass and increased fat oxidation in obese mice without the glucose and growth effects associated with unmodified growth hormone | Heffernan et al., 2001 (PubMed 11713213; PubMed 11673763) |
| Human program stage reached | Phase 2 metabolic trial in people with excess body fat, reported as not meeting its primary endpoint for body composition change | Program history; not independently confirmed by a peer-reviewed clinical paper identified for this article |
What Did the Preclinical Lipolysis Studies Measure?
The foundational work on this fragment was published by Heffernan and colleagues, who tested it in obese mouse models to separate its lipolytic activity from the growth-promoting and insulin-antagonist effects of full-length growth hormone. Full-length growth hormone mobilizes fat but also raises blood glucose and drives tissue growth through IGF-1 signaling, both effects the modified C-terminal fragment was designed to avoid. The chronic-treatment mouse studies measured body weight, fat pad mass, fat oxidation rate and blood glucose across the treatment window, comparing treated obese mice to untreated obese mice and, in one study design, to beta-3 adrenergic receptor knockout mice to test whether the lipolytic effect depended on that specific receptor pathway.
What Did the Mouse Data Actually Show?
Reported findings across the Heffernan papers describe reduced fat mass and increased fat oxidation in chronically treated obese mice relative to untreated controls, without the glucose elevation that chronic treatment with unmodified growth hormone produces in the same model. The Endocrinology paper specifically tested the fragment in beta-3 adrenergic receptor knockout mice, reporting that the lipolytic effect was at least partly dependent on that receptor pathway, a mechanistic detail that distinguishes this fragment's reported activity from a generic stimulant effect on metabolism. The companion paper in the International Journal of Obesity reported increased fat oxidation and reduced body weight in obese mice under a comparable chronic-treatment design, the clearest published pairing of mechanism and outcome for this compound in an animal model.
| Study | Model and n | Amount and route reported | Endpoint | Finding |
|---|---|---|---|---|
| Heffernan et al., Endocrinology, 2001 (PubMed 11713213) | Mouse, diet-induced obese cohorts and beta-3 adrenergic receptor knockout cohorts, chronic treatment groups | Subcutaneous or intraperitoneal fragment, chronic treatment across several weeks (exact milligram-per-kilogram amount as reported in the paper's methods) | Body weight, fat pad mass, fat oxidation rate, blood glucose | Reduced fat mass and increased fat oxidation in obese mice without the glucose-elevating effect of unmodified growth hormone; effect partly dependent on beta-3 adrenergic receptor signaling |
| Heffernan et al., Int J Obes, 2001 (PubMed 11673763) | Mouse, diet-induced obese cohorts, chronic treatment design compared with unmodified growth hormone | Subcutaneous or intraperitoneal fragment, chronic treatment across several weeks (amount as reported in the paper's methods) | Fat oxidation, body weight change | Increase in fat oxidation and reduction in body weight in obese mice, reported alongside the comparison growth hormone treatment group |
| Phase 2 metabolic trial (program history) | Human, adults with excess body fat, randomized, placebo-controlled, multi-month design reported in company and industry summaries | Subcutaneous administration, amount range used in the trial not independently confirmed for this article against a peer-reviewed source | Body composition change over the trial period; tolerability monitoring | Reported as not reaching a statistically significant separation from placebo on its primary body composition endpoint, a result that shifted later development interest toward other indications for the fragment |
The human Phase 2 metabolic program is the part of the AOD-9604 record this article is least able to independently verify against a peer-reviewed publication. Industry and program-history summaries describe a multi-month, randomized, placebo-controlled design in adults with excess body fat that did not separate from placebo on its primary body composition endpoint, which is consistent with why later interest in the fragment shifted toward other research areas, including connective-tissue research, rather than continued metabolic development. Readers should treat the specific amount, duration and participant count of that human trial as unconfirmed until checked against a primary clinical publication, in contrast to the mouse data above, which traces directly to peer-reviewed sources.
Why Did the Human Program Not Continue in the Metabolic Indication?
A finding of no statistically significant separation from placebo on the primary body composition endpoint is a common reason a sponsor does not continue a compound in a given indication, independent of whether the underlying mechanism is reproducible in animal models. The gap between a clear mouse lipolysis signal and a Phase 2 result that did not separate from placebo is not unusual in metabolic drug development generally; rodent adipose biology and human adipose biology differ in ways that can narrow or eliminate an effect seen in mice once a compound reaches a human efficacy trial. This is one of the reasons the AOD-9604 literature is weighted so heavily toward the mechanistic mouse studies: they are the part of the program that was published in full, peer-reviewed detail.
What Does the Earlier Metabolic Characterization Work Show?
Before the chronic-treatment obese-mouse studies, the same research group published work characterizing the fragment's metabolic activity more generally, including oral-administration experiments in mice intended to establish whether any lipolytic signal survived gastrointestinal exposure at all. That earlier work, along with a short report describing the fragment's lipolytic domain activity in isolation from the rest of the growth hormone molecule, is the foundation the later chronic-treatment obese-mouse and knockout-mouse papers built on. Taken together, this body of mouse-model work is consistent in reporting a lipolytic signal localized to the 177-191 region of growth hormone that is separable from the hormone's growth-promoting and glucose-raising activity, which is the mechanistic claim that carried the fragment into human development. At 15 amino acids, AOD-9604 is a small fragment of the roughly 191-residue full-length hormone, which changes its molecular weight, its expected retention behavior on reverse-phase HPLC, and its mass spectrometry signature relative to full-length growth hormone, a distinction that matters when reading a certificate of analysis for the research material. Program-history summaries also describe later research interest in the fragment shifting toward other areas, including connective-tissue research, after the metabolic Phase 2 result did not separate from placebo; that later shift is noted here as a general program-history point rather than a peer-reviewed finding, consistent with how the rest of the human-trial detail in this article is sourced.
How Does AOD-9604's Route of Administration Compare With Full-Length Growth Hormone?
The preclinical studies summarized above used parenteral administration (subcutaneous or intraperitoneal, depending on the specific experiment) in the mouse models, matching the route most peptide growth hormone fragments require because of digestive breakdown with oral delivery. The general principles behind why route matters for a peptide this size, including the comparison between parenteral and oral exposure, are described in peptide bioavailability by route. Background on the fragment's sequence and its relationship to the parent growth hormone molecule is covered in what is AOD-9604.
How this is handled in a research setting: AOD-9604 is supplied as a lyophilized powder and is reconstituted immediately before use in cell-based or animal-model work, following the concentration math described in reconstituting lyophilized peptides. Because the mouse literature above reports specific, replicable amounts and timelines, a lab repeating or extending this work should confirm the research-grade material's identity and purity against its certificate of analysis first; see how to read a peptide certificate of analysis for what each section of that document reports. Research-grade AOD-9604 sold for laboratory use carries no human or animal administration instructions.
Frequently asked questions
What part of growth hormone does AOD-9604 correspond to?
AOD-9604 corresponds to the C-terminal fragment of human growth hormone, residues 177 to 191, with an added modification intended to remove growth-promoting activity while preserving the lipolytic activity reported in that region of the parent molecule.
Why was a growth hormone fragment studied instead of full-length growth hormone?
Full-length growth hormone's metabolic effects are tied to insulin-antagonist and growth-promoting (IGF-1-mediated) activity that researchers wanted to separate from its fat-mobilizing activity. The fragment approach was designed to isolate the lipolytic signal from those other effects.
Did the mouse studies find any glucose-related findings?
Yes. The Heffernan et al., 2001 Endocrinology paper specifically reported that chronic treatment with the fragment did not produce the blood glucose elevation seen with chronic unmodified growth hormone treatment in the same obese mouse model.
Was there ever a published, peer-reviewed report of the human Phase 2 metabolic trial results?
This article could not independently confirm a peer-reviewed clinical publication reporting the full Phase 2 metabolic trial's amount, duration, participant count and statistical results. What is available comes from program-history and industry summaries, and that gap is flagged here rather than presented as a verified primary-source finding.
Does the beta-3 adrenergic receptor knockout data mean the effect only works through that one receptor?
The knockout-mouse comparison in Heffernan et al., 2001 indicated the lipolytic effect was at least partly dependent on beta-3 adrenergic receptor signaling, which narrows the proposed mechanism, but it does not by itself rule out contributions from other pathways not tested in that specific experiment.
Is AOD-9604's structure the same as the hGH fragment studied by other laboratories under different names?
The 177-191 hGH fragment has been studied by more than one laboratory group; AOD-9604 refers specifically to the modified version characterized in the Heffernan et al. papers and carried into the metabolic development program described here.
What model should a lab use to replicate the lipolysis findings?
The published, peer-reviewed data on this fragment's lipolytic activity comes from diet-induced obese mouse models and beta-3 adrenergic receptor knockout mouse models under chronic treatment designs, which is the model system a lab aiming to extend or replicate this specific mechanism would need to match.
References
- Heffernan MA, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. PubMed 11713213.
- Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442-1449. PubMed 11673763.
- Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. PubMed PMID.
- Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism in obese mice. Am J Physiol Endocrinol Metab. 2000;279(3):E501-E507. PubMed PMID.
Research use only. Homegrown Peptides products are for laboratory research and are not for human or animal use. Nothing in this article is medical advice.



